The survival rates of patients with FAK-overexpressing cancer were lower than those of patients without FAK-overexpressing cancer for those at stages T1N0, T1N1, T2N0, T2N1, and T3N1, but the difference was not significant. This evidence concerns the gene PTK2 and cancer.